Biomarkers to Predict Aggressive Prostate Cancer

Video   Mar 31, 2015

 


About the Speaker
Claire gained her PhD in 2002 and since then has worked in the field of cancer research. Claire has previously held a post at the prestigious MRC Cancer Cell Unit in Cambridge, UK before returning to Swansea University. Claire is now based at the Institute of Life Science where one of her research aims is concerned with identifying prognostic biomarkers for clinical management of prostate cancer and pancreatic cancer patients. Claire is also a Senior Lecturer in Genetics and teaches on the Genetics and Medical Genetics BSc degree schemes and Graduate Entry Medicine in the College of Medicine.Abstract
Prostate cancer (CaP) is the most common cancer in men in the UK. Every year nearly 40,000 cases of CaP are diagnosed and it accounts for approximately 12% of all male deaths from cancer in the UK. Early diagnosis of organ-confined CaP is essential since radical prostatectomy or radiotherapy offers the only chance of complete cure and treatment of advanced disease is palliative and in-effective (in the long term). In addition, early organ-confined CaP is not always life threatening and can follow and indolent course which does not require treatment. It is generally accepted that currently available methods used for diagnosis and staging of CaP (prostate specific antigen levels, Gleason score and clinical and pathological grade) lack the sensitivity to distinguish between patients with indolent, organ-confined CaP, those requiring radical treatment and those at risk of relapse after radical treatment. Clearly there is a need to identify molecular markers of CaP progression, invasion and metastasis to predict diagnosis and guide therapy. Due to the heterogeneous nature of cancer, analysis of single molecules provides limited information and it is impossible to diagnose cancer or predict disease progression using a single biomarker. Therefore there is a need to a identify a panel of biomarkers that may distinguish indolent cancer from aggressive metastatic disease when used collectively

 
 
 
 

Recommended Videos

Company Incorporates Pregnancy Test into Magazine Advert

Video

Mercene Labs has developed a very large pregnancy test integrated in a printed advertisement for IKEA. The finished ad appeared in the Swedish women’s magazine Amelia.

WATCH NOW

Immunology Wars: The Role of Monoclonal Antibodies

Video

Our immune systems are at war with cancer. This animation reveals how monoclonal antibodies can act as valuable reinforcements to shore up our defences – and help battle cancer.

WATCH NOW

Biggest Science News Stories of 2017

Video

We have seen some amazing scientific breakthroughs in 2017, here is a selection of our favourites.

WATCH NOW

 

Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Diagnostics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE